Health technology

China's Gathering Place for Innovative Medical Products: VBEF's 8th Future Healthcare Ecological Fair Will Be Held in Beijing Soon

Retrieved on: 
Wednesday, March 20, 2024
Research, Peking University, Health, Belt, Conference, Growth, Microbial metabolism, University, Synthetic biology, Elective surgery, School, AI, Biomaterials Science, VBEF, Outline of health sciences, National Health Commission, Exhibition, Ecosystem, Primary health care, Health technology, Convention center, Nuclear medicine, Belt and Road Initiative, Ophthalmology, Pharmaceutical industry

It will be held at the Beijing Beiren Yichuang International Convention and Exhibition Center from May 7th to 10th, 2024.

Key Points: 
  • It will be held at the Beijing Beiren Yichuang International Convention and Exhibition Center from May 7th to 10th, 2024.
  • The results interpret future trends to global medical innovators, demonstrate the linkage and cooperation between China's medical innovation technology and industry to the world, provide medical innovative products and solutions to the world, and demonstrate the true power of medical innovation.
  • In 2024, Vcbeat will upgrade the Future Medical Top 100 Conference held for seven consecutive years to the VBEF Future Healthcare Ecological Fair to help China's medical innovation industry accelerate the growth and promote a new medical innovation ecosystem.
  • Global medical industry practitioners are welcome to participate in the 8th VBEF Future Healthcare Ecological Fair in 2024.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

The Inner Circle acknowledges Jennifer A. Vazquez as a Pinnacle Lifetime Member

Retrieved on: 
Thursday, April 4, 2024
Kentucky Association, Biomedicine, Biomedical engineering, University, Biomedical technology, Growth, Projection, Central Florida, Learning, Knowledge, USB On-The-Go, AAMI, Biomedical equipment technician, DeVry University, Health technology, Health, Inner circle

CINCINNATI, April 4, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jennifer A. Vazquez is acknowledged as a Pinnacle Lifetime Member for her contributions in Medical Technology.

Key Points: 
  • CINCINNATI, April 4, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jennifer A. Vazquez is acknowledged as a Pinnacle Lifetime Member for her contributions in Medical Technology.
  • Jennifer A. Vazquez, a dynamic professional in the field of medical technology, has garnered recognition for her exceptional contributions and achievements in biomedical engineering.
  • With an impressive educational background and a commitment to excellence, Jennifer has established herself as a rising star in the industry.
  • Jennifer A. Vazquez attributes her success to the guidance and mentorship she has received from individuals such as Mr. Edward Reyes and Mr. Enrique Vazquez.

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, "A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

Ascend taps Snetor Group for Latin America and medical engineered materials distribution in Europe

Retrieved on: 
Tuesday, March 12, 2024
Partnership, Polymer, Ascend, Plastic, Health technology, Engineering

Snetor will distribute its polyamide-based engineered materials in Latin America, as well as Ascend's HiDura® MED portfolio for medical applications in Europe.

Key Points: 
  • Snetor will distribute its polyamide-based engineered materials in Latin America, as well as Ascend's HiDura® MED portfolio for medical applications in Europe.
  • This marks Ascend's first distribution agreement in Latin America since acquiring its compounding site in San José Iturbide, Mexico in 2022.
  • Snetor now carries Ascend's Vydyne®, Starflam®, HiDura and ReDefyne™ PA66, PA610 and PA612 resins and engineered materials in Europe and Latin America.
  • Snetor has been active in the distribution of plastic raw materials (from polymers commodities to engineering plastics) and chemicals in Latin America, Europe, Africa and the Middle East.

Ascend taps Snetor Group for Latin America and medical engineered materials distribution in Europe

Retrieved on: 
Tuesday, March 12, 2024
Partnership, Polymer, Ascend, Plastic, Health technology, Engineering

Snetor will distribute its polyamide-based engineered materials in Latin America, as well as Ascend's HiDura® MED portfolio for medical applications in Europe.

Key Points: 
  • Snetor will distribute its polyamide-based engineered materials in Latin America, as well as Ascend's HiDura® MED portfolio for medical applications in Europe.
  • This marks Ascend's first distribution agreement in Latin America since acquiring its compounding site in San José Iturbide, Mexico in 2022.
  • Snetor now carries Ascend's Vydyne®, Starflam®, HiDura and ReDefyne™ PA66, PA610 and PA612 resins and engineered materials in Europe and Latin America.
  • Snetor has been active in the distribution of plastic raw materials (from polymers commodities to engineering plastics) and chemicals in Latin America, Europe, Africa and the Middle East.

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Eli Lilly, CFO, Acquisition, OPCH, Mallinckrodt, Syneos Health, Hospira, SVP, OTC, ENOV, Growth, BioMarin Pharmaceutical, MBA, Hill-Rom, NorthStar, CDMO, Doctor of Philosophy, University, Engineering, Partnership, Radiopharmaceutical, McKinsey & Company, Patient, Invacare, IVC, Northwestern University, Health technology, Cancer, Management

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.

Key Points: 
  • NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024.
  • "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar.
  • She is currently a Board Director for Enovis Corporation (NYSE: ENOV), Option Care Health (NASDAQ: OPCH) and BioMarin Pharmaceutical (NASDAQ: BMRN).
  • “2024 and the next few years will be critical for NorthStar,” said Frank Scholz, Ph.D., NorthStar President and Chief Executive Officer.